The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Gilead Sciences to Present at Two Upcoming Investor Conferences

<p class='bwalignc'> <i><b>- 23</b></i><sup><i><b>rd</b></i></sup><i><b> Annual OC ROTH Growth Stock Conference on March 14</b></i><sup><i><b>th</b></i></sup><i><b> -</b></i><br/><i><b>- Barclays Capital 2011 Global Healthcare Conference on March 15</b></i><sup><i><b>th</b></i></sup><i><b> -</b></i><br/><i><b>- Webcasts Available Through Gilead Corporate Website -</b></i> </p> <p class='bwalignc'> </p>

Monday, March 07, 2011

Gilead Sciences to Present at Two Upcoming Investor Conferences16:30 EST Monday, March 07, 2011 FOSTER CITY, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: the ROTH Growth Stock Conference in Dana Point, California and the Barclays Global Healthcare Conference in Miami. John F. Milligan, PhD, Gilead's President and Chief Operating Officer, will provide an overview of the company at the ROTH conference on Monday, March 14 at 12:30 p.m. Pacific Daylight Time (3:30 p.m. Eastern Daylight Time (EDT). Kevin Young, Gilead's Executive Vice President, Commercial Operations, will provide an overview of the company at the Barclays conference on Tuesday, March 15 at 9:00 a.m. EDT. To access the live webcasts via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to each live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). Gilead Sciences, Inc.Susan Hubbard, 650-522-5715Investor Relations